Jornal Internacional de Inflamação, Câncer e Terapia Integrativa

Abstrato

Bevacizumab (Bmab) +Dihydropyrimidine Dehydrogenase (DPD) Inhibitory Fluor pyrimidine (DIF) Combined Chemotherapy for the Treatment of Late-Stage Elderly Patients with Advanced/Recurrent Colorectal Cancer (ARCC)

Kazuma Kobayashi

Objective: In Japan, the elderly represent more than 20% of the total population. The incidence of elderly patients with advanced/recurrent colorectal cancer (ARCC) has also increased. However, the optimal regimen for elderly patients, particularly those over 75 years of age (advanced elderly), has not been established.
Results: The STD was 979 days, the median PFS was 350 days, and the RR was 23.3%. Grade ≥3 AEs with each regimen were: Bob + DIF, 1.9%, other regimens, 14.4%. Although no significant difference was observed in OS or PFS between Bmab + DIF and other treatment regimens, the transition rate to 2nd line chemotherapy after disease progression after first-line treatment was higher with Bmab + DIF (54.6% [6/11]) than with other treatment regimens (38.9% [7/18]); however, this difference did not reach statistical significance